chemoradiotherapy for rectal cancer
DESCRIPTION
Chemoradiotherapy for Rectal cancer. Dr. A . Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology. Association of Coloproctology of Great Britain and Ireland M62 Coloproctology Course - March 23 rd 2007. Background. - PowerPoint PPT PresentationTRANSCRIPT
Chemoradiotherapy for Rectal cancer
Dr. A . Sun MyintLead Clinician GI Tumour Group
Clatterbridge Centre for Oncology
Association of Coloproctology of Great Britain and Ireland
M62 Coloproctology Course - March 23rd 2007
Background
• In the UK over 10,000 new rectal cancer
• Five year survival 50% (NBOCAP-2006)
• Nearly half will develop recurrences
• At presentation 30% T3/T4 N + MO
• Preoperative radiotherapy reduce LR
• So far, no survival advantage
Treatment Options
• Surgery TME / Training
Sub specialisation
• Radiotherapy Pre operative
Chemoradiotherapy
Post operative• Chemotherapy Advance /metastatic
Adjuvant
New agents
Options Improvements
Radiotherapy
Preoperative Radiotherapy
Short course or Long course?• Short course
• Long course
Preoperative Radiotherapy
Short course or Long course?• Short course - Mobile operable tumour
• Long course - Fixed / Tethered tumour
30%( MRI defined CRM +)
Preoperative Radiotherapy
Short course or Long course?• Short course - Mobile operable tumour
• Long course - Fixed / Tethered tumour
( MRI defined CRM +)
Improving Outcomes
• Add chemotherapy to radiation
• Increase radiation dose
Chemo-radiotherapy
Concurrent Chemotherapy + RT• 5FU
• 5FU / FA
• 5FU infusion + Irino / Oxaliplatin
• Capecitabine + Irino / Oxaliplatin+ EGFR
• Capecitabine + Irino / Oxaliplatin+ VEGFR
Oxaliplatin is a radiosensitiser
in HT-29 xenograft models Tumour volume
Days post-treatment
Oxaliplatin + radiation
Blackstock A et al. Int J Rad Oncol Biol Phys 2000;16:92–94
Control
Oxaliplatin 5mg/kg
Radiation only (5Gy)
160
120
80
40
001 05 09 13 17 21
Comparative tumor sterilization rate by treatment modality
Treatment
modality
pCR + pMic RO
EBRT alone 7.1% (26%) 40%
EBRT+ chemo 16.2% (31%) 60%
EBRT+ duplet 21% (60%) 90%
Is chemo-Radiotherapy better than RT alone?
EORTC Rectal cancer trial
Pre-op RT SURGERY
Pre-op
Chemo/RT
SURGERY
Pre-op RT SURGERY Adjuvant
Chemo
Pre-op
Chemo/RT
SURGERY Adjuvant
Chemo
T3/T4 rectal cancer n=1011
EORTC Rectal cancer trial
Pre-op
Chemo/RT
Pre-op RT
Local recurrence
8.7% 17%
(p=0.0016)
Bossett al ASCO 2005
EORTC Rectal cancer trial
Adjuvant
Chemo
No Adjuvant
Chemo
Survival 67.2% 63.2%
Bossett al ASCO 2005
FFCD 9203- Rectal cancer trial
Pre-op RT SURGERY
Ad Chemo
Pre-op CRT SURGERY
Ad Chemo
JP Gerard et al ASCO 2005
T3/T4 rectal cancer n=733
FFCD 9203- Rectal cancer trial
Pre-op
Chemo/RT
Pre-op RT
Local recurrence
8.0% 16.5%
JP Gerard et al ASCO 2005
FFCD 9203- Rectal cancer trial
Adjuvant
Chemo
No Adjuvant
Chemo
Survival 67% 66%
JP Gerard et al ASCO 2005
Chemo RT vs. Radiotherapy
Trials
Pre-op CRT
Pre-op RT
EORTC 22921 8.7% 17.1%
FFCD 9203 8% 16.5%
German-94 6%
Local control in T3/T4 rectal cancer
Pre-operative Radiotherapy better than
post op RT?
German pre op. vs. post operative chemoradiotherapy for rectal cancer
Preoperative
Chemo-RT
Surgery
Surgery Post operative
Chemo-RT
Sauer et al N Engl J Med (2004) 351;17 1731-01740
German pre op. vs. post operative chemoradiotherapy for rectal cancer
Pre op
n=405
Post op
n=394
Local recurrence
6% 13% P=0.0006
Survival 76% 74% P=0.08
Sauer et al N Engl J Med (2004) 351;17 1731-01740
German pre op. vs. post operative chemoradiotherapy for rectal cancer
Pre op
n=405
Post op
n=394
Acute
Toxicity
27% 40%
P=0.001
Late
Toxicity
14% 24% P=0.01
Sauer et al N Engl J Med (2004) 351;17 1731-01740
Newer agents for chemoradiotherapy
Chemoradiotherapy
• 5FU bolus
• 5FU+ FA
• Infusional 5FU
• Capecitabine• Irinotecan +Cape NWCCOG 1+ RICE
• Oxaliplatin +Cape CORE/ SOCRATES
• Triplet therapy Ir/Oxali + MdG+ VEGF
RADIOTHERAPY
Pre-operative 5-FU chemoradiation:
• 5-FU-based chemoradiation has become part of standard pre-operative therapy for rectal cancer
– effective downstaging
– 10–30% pCR rates
• Protracted infusion of 5-FU with postoperative radiotherapy improves survival versus bolus
5-FU1
1O’Connell MJ et al. N Engl J Med 1994;331:502–7
Infused versus bolus 5-FU during pelvic radiation
O’Connell MJ et al. N Engl J Med 1994;331:502–7
100
80
60
40
20
00 1 2 3 4
Years after randomisation
Overall survival (%)
Log rank p=0.005
Cox model p=0.01
Infused 5-FU (n=328)
Bolus 5-FU (n=332)
Capecitabine + radiation
capecitabine plus radiotherapy
• Infused 5-FU is cumbersome and inconvenient for patients
• Oral capecitabine simplifies chemoradiation and is highly appealing to patients
• Potential for enhanced therapeutic ratio
– capecitabine generates 5-FU preferentially in tumour via
thymidine phosphorylase (TP)1
– radiotherapy further upregulates TP in tumour2
1Miwa M et al. Eur J Cancer 1998;34:1274–812Sawada N et al. Clin Cancer Res 1999;5:2948–53
Irradiation upregulates TP
25
20
15
10
5
0
TP (units/mg protein)
0 3 6 9 12 15 18 21Days after X-ray irradiation
*
*
*
**
* *
*
*
*p<0.05
5Gy
2.5Gy
Control
Sawada N et al. Clin Cancer Res 1999;5:2948–53
120
100
80
60
40
20
0
capecitabine enhances activity of radiation in WiDr xenografts,
Tumour inhibition (%)
*
Sawada N et al. Clin Cancer Res 1999;5:2948–53
5Gy
Xeloda
Xeloda
+ 5G
y5-
FU
5-FU +
5Gy
*p<0.05
Capecitabine chemoradiation:
• Oral capecitabine is replacing 5-FU in chemoradiation
– capecitabine is highly effective and well tolerated in combination with radiotherapy
– capecitabine simplifies chemoradiation and is highly appealing to patients and clinicians alike
Chemoradiation in rectal cancer: German phase II study (n=68)
• Male / female (%) 63 / 37
• Median age 65 years
• ECOG 0/1 (%) 54 / 41
• T3 / T4 (%)48 / 52 (57% N1–3)
Day 1 8 15 22 29 35
50.4Gy radiotherapy1.8Gy / fraction
825mg/m2
twice dailyContinuous (days 1–37)
Dunst J et al. Proc Am Soc Clin Oncol 2003;22:277 (Abst 1113)
capecitabine chemoradiation:efficacy
1Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282) 2Lin E et al. Proc Am Soc Clin Oncol 2003;22:287 (Abst 1152)
Patients (%)
Dunst study1 Lin study2
Down staging 79 73
pRR 80 87
pCR 5 20
Patients (%)
Diarrhoea Local Pain Hand-foot Nausea erythema syndrome
Grade 1/2
Grade 3
Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282)
capecitabine chemoradiation: Toxicity
• No grade 4 adverse events80
60
40
20
0
NSABP R-04 rectal cancer trial
*Plus 5.4Gy for fixed tumours
Resectable rectal cancer, stage II–III
n=1600
capecitabine continuously throughout
radiotherapy (50.4Gy*)SURGERY
5-FU continuous infusion throughout
radiotherapy (50.4Gy*)
Objectives – DFS– recurrence rate– pCR– safety
Chemoradiation using Oxaliplatin combination
capecitabine/oxaliplatin chemoradiation
Patients (%)
Glynne-Jones1
(n=16) Rödel2 (n=31)
pCR 31 19
pT1 / 2N0 19 23
Resection margin
R0 88 94
R1 12 6
1Glynne-Jones R et al. Proc Am Soc Clin Oncol 2003;22:292 (Abst 1174)2Rödel C et al. J Clin Oncol 2003;21:3098–104
CORE: European study
Radiotherapy45Gy / 25 fractions
capecitabine825mg/m2 twice daily
Monday to Friday
Oxaliplatin50mg/m2
weekly
1 8 15 22 29Day
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Chemoradiotherapy using Irinotecan combination
RICE - NWCCOG study
Radiotherapy45Gy / 25 fractions
capecitabine825mg/m2 twice daily
Monday to Friday
IRINOTECAN
60mg/m2 weekly
1 8 15 22 29Day
S. Gollins, S.Myint, E. Levine et al Proc Am Soc Clin Oncol 2006;24:617s (Abst 13519)
Chemoradiotherapy
• 5FU bolus
• 5FU+ FA
• Infusional 5FU
• Capecitabine• Irinotecan +Cape NWCCOG 1+ RICE
• Oxaliplatin +Cape CORE/ SOCRATES
• Triplet therapy Ir/ Oxali + cape+ EGF
RADIOTHERAPY
ARISTOTLE
Reducing Toxicity from CRT
Toxicity
• Chemoradiotherapy is more toxic than radiotherapy alone
• To reduce toxicity:-Preoperative rather than post
opRadiation volumeDose, fractionation and timeRadiation techniques
Are there any other options to reduce toxicity
from chemoradiation?
Improving Outcomes
• Add chemotherapy to radiation
• Increase radiation dose
Increasing Radiation dose• External Beam ( 45 Gy /25# /35)
• EBRT +Boost ( 50.4Gy/28#/38)
• EBRT + Contact RT boost (60-80Gy)
• EBRT + Contact HDR boost
Papillon Technique
Radical contact radiotherapy
Lyon R96-02 Trial
Results EBRT EBRT+ boost
Clinical CR ( 2% ) (24%)Path CR/micro (34%) (57%)p=.027
Sphincter (44%) (76%)p=.004
JP Gerard et al. J Clin Oncol 2004 :22 2404-2409
Lyon R96-02 Trial
Results EBRT EBRT + Boost
L R 3% 1%Morbidity 43% 38%LR Survival 88% 92%
JP Gerard et al J Clin Oncol 2004 :22 2404-2409
HDR Rectal Brachytherapy
20mm
5mm
Pre op HDR Brachytherapy
Pathology• T0N0 29%
• Micro 37%
• Residual 34%
• N+ 31%
• T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst: 1062
Pre op HDR Brachytherapy
Results• Median FU 37months• 5years Local recurrence 3%
DFS 65% OS 74% CSS 84%
• Toxicity G3 1% (30% CRT)
T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst: 1062
Comparative tumor sterilization rate by treatment modality
TREATMENT pCR (pMic) RO
EBRT alone 7.1% (26%) 40%
CT+ EBRT 13% (31%) 60%
EBRT+contact 21% (60%) NA
HDR alone 29% (66%) 97%
CT+EBRT+
HDR boost
40%? (80%) 100?
Treatment Options
• Surgery T1/T2/T3 / N+
(clear CRM)
• Pre op chemo RT r CRM <1mm
(sphincter preservation)
• Post op chemo RT p CRM<1mm
(node +ive)
• Radical RT T1/T2/ N0
Conclusions-1
• All cases with rectal cancer should be discussed at the MDT
• MRI scan is essential for pre operative assessment
• Pre operative chemoradiotherapy offers better local control than pre operative radiotherapy alone
Conclusions-2
• Pre operative chemoradiotherapy is more effective and less toxic than post operative
chemoradiotherapy
• Nearly half the patients with rectal cancer will develop recurrences; however no DFS or overall survival benefit has been shown with adjuvant chemotherapy in any of the trials published so far.
It is important to contribute to clinical
trials